New macrolide antibiotic Rapamycin looks to be an excellent choice
for rosacea. It inhibits angiogenesis by approximately 90%, blocks
VEGF production (one key to rosacea) and inhibits neutrophil
chemotaxis (the cause of rosacea papules). We get a lot of
questions about why to take angiogenesis blockers post laser and if
they really work. Yes, they certainly do. If you type into pubmed,
Macrolide antibiotics and antiangiogenesis you will come up with
hundreds of studies showing this effect.

Regards,

Geoffrey
______________________________

Dr. Geoffrey Nase
Ph.D. Neurovascular Physiologist
http://www.drnase.com
______________________________



Nat Med. 2002 Feb;8(2):128-35. Related Articles, Links

•
Rapamycin inhibits primary and metastatic tumor growth by
antiangiogenesis: involvement of vascular endothelial growth factor.


Conventional immunosuppressive drugs have been used effectively to
prevent immunologic rejection in organ transplantation. Individuals
taking these drugs are at risk, however, for the development and
recurrence of cancer. In the present study we show that the new
immunosuppressive drug rapamycin (RAPA) may reduce the risk of
cancer development while simultaneously providing effective
immunosuppression. Experimentally, RAPA inhibited metastatic tumor
growth and angiogenesis in in vivo mouse models. In addition, normal
immunosuppressive doses of RAPA effectively controlled the growth of
established tumors. In contrast, the most widely recognized
immunosuppressive drug, cyclosporine, promoted tumor growth. From a
mechanistic perspective, RAPA showed antiangiogenic activities
linked to a decrease in production of vascular endothelial growth
factor (VEGF) and to a markedly inhibited response of vascular
endothelial cells to stimulation by VEGF. Thus, the use of RAPA,
instead of cyclosporine, may reduce the chance of recurrent or de
novo cancer in high-risk transplant patients.